Tucson, AZ, United States of America

Lisa M LaGrandeur

This inventor holds 2 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lisa M LaGrandeur. Retrieved from https://idiyas.com/inventor/lisa-m-lagrandeur

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Lisa M LaGrandeur

Introduction

Lisa M LaGrandeur is a prominent inventor based in Tucson, AZ. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antifungal agents. With a total of 2 patents to her name, her work has had a notable impact on medical science.

Latest Patents

Lisa's latest patents focus on cyclic peptide antifungal agents. These patents provide pharmaceutical formulations and methods for inhibiting fungal and parasitic activity using specific compounds. The detailed formulations are designed to enhance the effectiveness of treatments against various fungal infections.

Career Highlights

Throughout her career, Lisa has been associated with Eli Lilly and Company, a leading pharmaceutical firm. Her work has been instrumental in advancing the company's research and development efforts in antifungal therapies.

Collaborations

Lisa has collaborated with notable colleagues, including Michael J Rodriguez and Mark J Zweifel. These partnerships have fostered innovation and contributed to the success of her projects.

Conclusion

Lisa M LaGrandeur's contributions to the field of pharmaceuticals exemplify the importance of innovation in healthcare. Her work continues to inspire advancements in antifungal treatments and showcases the vital role of inventors in improving medical outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…